Improving delivery of antineoplastic agents with anti-vascular endothelial growth factor therapy

Anthony D. Yang, Todd W. Bauer, E. Ramsay Camp, Ray Somcio, Wenbiao Liu, Fan Fan, Lee M. Ellis

Research output: Contribution to journalArticlepeer-review

38 Scopus citations


It is believed that impairments in delivery of antineoplastic agents to solid tumors result from abnormalities of the tumor microenvironment. Vascular endothelial growth factor (VEGF), the prototypical angiogenic molecule, is one of the main factors responsible for the development and maintenance of the aberrant tumor vascular network, which is characterized by chaotic, leaky blood vessels with high interstitial fluid pressure and inefficient blood flow. The authors proposed that anti-VEGF therapy would reduce the elevated interstitial fluid pressure in tumors, thereby improving blood flow and potentially improving delivery of cytotoxic agents to tumor cells. For the current report, the authors reviewed characteristics of the abnormal tumor vasculature created under the influence of VEGF, the resulting tumor microenvironment, how the tumor microenvironment may impede delivery of antineoplastic agents, and how the combination of anti-VEGF and cytotoxic therapy may maximize the efficacy of antineoplastic treatment regimens.

Original languageEnglish (US)
Pages (from-to)1561-1570
Number of pages10
Issue number8
StatePublished - Apr 15 2005
Externally publishedYes


  • Angiogenesis
  • Chemotherapy
  • Endothelial cell
  • Interstitial fluid pressure
  • Permeability
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Improving delivery of antineoplastic agents with anti-vascular endothelial growth factor therapy'. Together they form a unique fingerprint.

Cite this